Sotera Health Co. 10-Q Summary: Q2 2025
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Sotera Health Co. is a global provider of sterilization solutions, lab testing, and advisory services. The company operates through three reportable segments: Sterigenics (terminal sterilization), Nordion (Co-60 supply and irradiation systems), and Nelson Labs (microbiological and analytical testing).
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Net Revenues | $294.3 million | $276.6 million | $548.9 million | $524.8 million |
| Gross Profit | $166.6 million | $152.8 million | $302.1 million | $279.9 million |
| Net Income (Loss) | $8.0 million | $8.8 million | $(5.3) million | $15.1 million |
| Adjusted EBITDA | $150.7 million | $137.3 million | $272.6 million | $249.3 million |
| Operating Cash Flow (YTD) | $112.9 million (vs. $71.0 million YTD 2024) | |||
| Cash & Equivalents | $332.4 million (as of June 30, 2025) | |||
| Total Debt (Net) | ~$2.22 billion (Long-term) + $14.8 million (Current) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2025 revenues increased 6.4% year-over-year, driven by an 8.2% increase in service revenues (volume/mix improvements and pricing) partially offset by a 4.5% decline in product revenues (timing of Co-60 harvests).
- Profitability Impact: While Q2 GAAP net income was positive ($8.0M), the YTD 2025 period resulted in a net loss of $5.3M compared to $15.1M income in YTD 2024. This was primarily due to $64.9 million in Illinois EO litigation settlements recorded in the first half of 2025.
- Expense Increases: SG&A expenses rose 13.7% in Q2 and 11.1% YTD, largely driven by a $14.3 million increase in litigation and professional services fees related to Ethylene Oxide (EO) sterilization facilities.
- Amortization: Amortization of intangible assets decreased significantly (39.7% in Q2) due to certain assets becoming fully amortized in May 2025.
Guidance, Outlook, and Risks
- EO Litigation Settlements: The company entered into binding term sheets to resolve 226 pending/threatened EO claims in Illinois (Willowbrook facility) for a total of $64.9 million ($30.9M in April, $34.0M in July). These settlements are subject to court approval and 100% claimant participation.
- Other Legal Proceedings: Significant litigation continues in Georgia (Atlanta facility), California (Vernon facility), and New Mexico (Santa Teresa facility). The company notes that insurance limits for these claims have been fully utilized.
- Debt Refinancing: In April 2025, the company amended its Revolving Credit Facility (Amendment No. 5), increasing commitments by $176.2 million and extending the maturity to April 2030. Total revolver availability is $585.8 million.
- Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed July 4, 2025, but does not currently expect a material impact on operations.
- Forward-Looking Risks: Key risks include supply chain disruptions for EO and Co-60, geopolitical instability, foreign currency fluctuations, and the potential for additional EO tort claims or unfavorable trial outcomes in pending jurisdictions.
Investor Verification Checklist
- Settlement Finalization: Verify the status of the Illinois EO settlements (April and July term sheets) and whether court approval has been granted.
- Insurance Recovery: Review the status of the insurance coverage lawsuits (e.g., Northern District of Illinois) to determine potential recoveries for defense costs and settlements.
- Segment Performance: Monitor Nordion's product revenue volatility due to Co-60 harvest schedules and Sterigenics' volume/mix trends.
- Debt Covenants: Confirm continued compliance with leverage ratios and other covenants under the Senior Secured Credit Facilities and Secured Notes.
- Future Litigation Exposure: Assess the company's ability to defend against ongoing and threatened EO lawsuits in Georgia, California, and New Mexico, given the exhaustion of current insurance limits.